In a recent interview, Danny Williams, president of channel management and 3PL at EVERSANA, discussed transformative trends in pharmaceutical logistics, specifically the integration of artificial intelligence (AI) and the challenges posed by cell and gene therapies (CGTs).
Williams highlighted a significant shift in the use of AI within the supply chain, moving from experimental pilots to essential operational applications. These advancements now encompass demand forecasting, inventory management, and proactive risk identification. He emphasized that the effectiveness of AI is no longer in question; the focus has shifted to how 3PLs can scale these technologies consistently to ensure reliable outcomes for both manufacturers and patients. Responsible AI adoption, according to Williams, necessitates the establishment of appropriate standards to guide its deployment.
Transitioning to cell and gene therapies, Williams explained the unique logistical requirements that differentiate CGTs from traditional pharmaceuticals. Unlike conventional small molecule drugs, which can be produced in batches, CGTs are often personalized, requiring meticulous coordination throughout the supply chain. This involves stringent temperature controls, enhanced chain of custody protocols, and precise timing between manufacturing and administration. The industry is currently investing significantly to build the necessary infrastructure to support these complex therapies, making operational precision a critical priority.
As the pharmaceutical landscape evolves with AI and CGTs, the implications for 3PL providers are profound. The need for advanced logistics solutions that can adapt to the personalized nature of CGTs, combined with the scalable application of AI, will likely define the future of pharmaceutical distribution and patient care.